Taiwan firm strikes Japanese prostaglandin deal
This article was originally published in Scrip
Executive Summary
Taiwan Liposome Company (TLC) has linked up with the Japanese generics firm Nihon Generic for the development and marketing in Japan of a stable liposome formulation of the peripheral vasodilator prostaglandin E1 (alprostadil). The main branded version of lipo-alprostadil in Japan is co-marketed by Taisho and Mitsubishi Tanabe Pharma as Palux/Liple and is forecast to have total sales of close to ¥20 billion ($185.5 million) this fiscal year. Several other companies also market alternative lipo-alprostadil preparations. TLC has developed proprietary liposome-based encapsulation technology which it says inhibits the degradation of alprostadil, and is also developing formulations in the oncology field.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.